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S340 Poster Session IIcyclophosphamide 60 mg/kg/day D-6 to -5, and 14.4Gy total body
irradiation in 8 fractions D–3 to 0, with 20mg alemtuzumab added
to the bag in vitro, and cyclosporin as GVHD prophylaxis.
Median follow-up for surviving patients was 52 months. All pa-
tients engrafted, at a median of 11 days for neutrophils and 10 days
for platelets. Acute GvHD grade II-IV occurred in 16% (3/9 grade
.II) and extensive chronic GvHD in 27%, which was cutaneous
only in 10/13, and responded to prolonged cyclosporin alone or
short course systemic corticosteroid. Non-relapse mortality
(NRM)was 23% at 5 years, and estimated relapse risk 26%at 5 years.
Estimated event-free survival (EFS) was 54% at 5 years. Complete
remission at the time of transplant and the presence of any chronic
GVHD favourably impacted EFS, with HLA mismatching confer-
ring no disadvantage.
Use of this regimen therefore permits the successful transplanta-
tion of patients with high-risk disease using unrelated donors, with
no negative impact of HLA-mismatching at one and two loci (12
and 9 patients respectively), minimal acute GvHD, a modest rate
of chronicGVHDwhich was largely confined to skin and was readily
treatment-responsive, and no evidence of an excessive relapse rate.
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IMPACT OF A LOWER BUSULFAN AREA UNDER THE CONCENTRATION-
TIME CURVE (AUC) DOSING TARGET ON ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION (HCT) OUTCOMES
CruzChacon, A.M.1, Perkins, J.B.1, Pidala, J.A.1, Kim, J.2, Yue, B.2,
Field, T.1, Anasetti, C.1 1Moffitt Cancer Center, Tampa, FL; 2Moffitt
Cancer Center, Tampa, FL
Busulfan systemic exposure, as measured pharmacokinetically by
area under the concentration-time curve (AUC), has been correlated
with transplant-related toxicity and efficacy. Attempting to reduce
morbidity and mortality in patients (pts) 60 years (yrs) or older
and/or those with significant comorbidity, we have pharmacokineti-
cally-targeted a lower daily busulfan AUC of 3500 mmol x min/L
compared to 5300 used in other pts. To evaluate the effectiveness
of this strategy, we retrospectively compared outcomes in 345 con-
secutive pts with hematologic malignancies receiving busulfan and
fludarabine from 7/04-10/09. 44 pts were targeted to busulfan
AUC of 3500 and were more likely to receive a matched unrelated
graft (p 5 0.038), have CLL, indolent NHL, or MDS (p\0.0001)
and a high risk of relapse as defined by CIBMTR criteria
(p\0.0001) compared to the AUC 5300 cohort. The median age
was 62 yrs for the AUC 3500 pts and 48 yrs for AUC 5300 pts
(p\0.0001). There were no significant differences in CMV serology,
HCT-CI scores, Karnofsky performance status (KPS), or history of
prior transplant. When adjusted for CMV serology, donor, diagno-
sis, HCT-CI, KPS, and age, busulfan AUCwas not a significant pre-
dictor of overall survival or cumulative incidence of nonrelapse
mortality. However, busulfan was an independent factor in a multi-
variable model for relapse-free survival (RFS) (HR 1.67; 95% CI
1.13-2.48) and of borderline significance in a multivariable model
of cumulative incidence of relapse (HR 1.7; 95%CI 0.98-2.93).
The 2-year estimate of RFS in the AUC 3500 pts was 21.9% vs
44.1% in the AUC 5300 pts. The cumulative incidence of relapse
at 2 years in the AUC 3500 was 41% vs. 31% in the AUC 5300
pts. This would suggest that careful consideration should be made
in choosing to reduce busulfan AUC as a reduction in intensity
may lead to reduced efficacy. These results should be interpreted
with caution due to the limitations of multivariable analysis of retro-
spective data as other patient characteristics may exist that cannot be
accounted for in this type of analysis.
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FLUDARABINE BASED PREPARATIVE REGIMEN CAN SECURE A SECOND
HEMATOPOIETIC STEM CELL TRANSPLANT AFTER INITIAL GRAFT REJEC-
TION
Tamari, R.1, Boulad, F.2, Papadopoulos, E.B.1, Kernan, N.A.2,
Jakubowski, A.1, Small, T.N.2, Perales, M.A.1, O’Reilly, R.J.2,
Young, J.W.1, Giralt, S.1, Barker, J.1, Castro Malaspina, H.1 1Memorial
Sloan Kettering Cancer Center, New York, NY; 2Memorial Sloan Ketter-
ing Cancer Center, New York, NY
Graft rejection after allogeneic stem cell transplantation (HSCT)
is a rare but often fatal complication.The optimal preparative regi-men for engraftment of a second transplant has not been well de-
fined. We previously described our experience in HSCT-2 for
graft rejection in 16 pts, we report here a larger series.
Patients&Methods:From1997- 2010, 24 pts underwent aHSCT-
2 for graft rejection. Median age was 19.8 years (range: 1- 61). All pts
were conditioned for HSCT-1 with myeloablative preparative regi-
men (TBI or busulfan-based) for acute chronic leukemia (N5 11/2),
MDS (N5 7) or congenital hematopoietic non-malignant disorders
(N 5 4). 20 of the first transplants were TCD. The donors for the
first transplant were: HLA matched related/unrelated (N 5 4/6),
HLA mismatched related/unrelated (N 5 3/11).The preparative
regimen for the second transplant consisted of Fludarabine (Flu)
(30 mg/m2/d/5 days) plus Cyclophosphamide (Cy) (60 mg/kg/d/2
days) (N 5 13), Flu (25 mg/m2d/ 5 days) plus Thiotepa (5 mg/kg/
d/2 days) (N 5 5), Cy (60 mg/kg/d/2 days) plus Thiotepa (5 mg/
kg/d/2 days) (N 5 3), Flu (30 mg/m2d/5 days) (N 5 2), Cy plus
low dose TBI (N 5 1). Thus, 19 of the 24 pts (79%) were condi-
tioned for HSCT-2 with a Flu based regimen. Pts also received
ATG (N 5 19) or Campath (N 5 5). The donors for HSCT-2
were: HLA-matched related/unrelated (N5 4/3), HLAmismatched
related/unrelated (N 5 10/7). The original donor was used in 8/24
cases. The grafts administrated were unmodified PBSCT (N 5 8),
unmodified BMT(N 5 2) or TCD PBSCT (N 5 14). The median
CD34/kg infused in the second transplant was 11.8x106CD34/kg
(2.8-34x106CD34/kg).
Results:All pts engrafted with a median of 13 (9-26) days; full donor
engraftment was documented in 21 (88%) pts. GVHD developed in
8 (33%) pts (aGvHD-7, cGvHD-1), 3 had received a TCD graft and
5 an unmodified graft. CMV and EBV reactivations occurred in 6
(25%) patients with 2 cases of EBV-LPD and 1 case of CMV pneu-
monitis. The preparative regimen for the second transplant was well
tolerated with minimal mucositis, and only one serious adverse
event: veno-occlusive disease. Twelve pts (50%) are alive with a me-
dian follow up time of 9.75 years (1.75-13.5 years); 9 pts (64%) re-
ceived a TCD transplant and 3 pts (30%) an unmodified transplant.
Conclusion: In this cohort of pts who underwent a HSCT-2, either
unmodified or TCD, Flu based chemotherapy conditioning was able
to assure engraftment with a relatively low toxicity profile and long
term survival.
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OUTCOMES OF SECOND TRANSPLANTS FOR DISEASE RECURRENCE OR
FOR MYELODYSPLASIA (MDS) DEVELOPING AFTER AN INITIAL TRANS-
PLANT (Tx)
Naik, S., D’Agostino, R. Jr., Lamar, Z., Graham, R.M., Vatca, M.,
Agnew, E., Higgins, A., Levitan, D., Hurd, D.Wake Forest Baptist Med-
ical center, Winston-Salem, NC
Introduction: Treatment options for persons who relapse after an
initial transplant (autologous [AutoTx] or allogeneic [AlloTx]) or
who develop MDS following an AutoTx are limited. Current treat-
ment options include chemotherapy, donor leukocyte infusions
(DLI) (if alloTx) and a second transplant. A second transplant may
be effective salvage therapy in some patients (pts) who relapse or
who develop MDS after their initial Tx if an allo donor can be
identified.
Methods: A total of 1808 transplants were performed at Wake For-
est Baptist Hospital from May 1990 through July 2011 and 1525 Tx
(84%) were performed for diagnosis of a hematological malignancy.
Of these, 52 pts (3%) received a second Tx for disease recurrence or
therapy relatedMDS.The diagnosis at the time of first transplant in-
cluded acute and chronic leukemia (n 5 15); lymphoma (n 5 16);
myeloma (n 5 16); MDS: MF (n 5 4(3:1)); germ cell tumor (n 5
1). An additional 7 pts who received second transplant were excluded
from analysis (1: aplastic anemia pt; 5 for planned tandem AutoTx;
one for insufficient data. Transplants were either Auto / Auto
(for relapse; n 5 12); Allo/ Allo (for relapse; n 5 9); or Auto/
Allo (for relapse or the development of MDS; n 5 31).
Results: Patient characteristics are presented in Table 1.PB (pe-
ripheral blood) was the most common graft type in 43 pts (n5 83%).
Median time to second transplant was 1.8 years (0.27-18 yrs). Total
body irradiation (TBI) was given in 17 % (n 5 9) pts during first
transplant and 6 % (n 5 3) pts during second transplant. Reduc-
ed-intensity regimen (Flu/Bu) was used in 42 % (n 5 22) pts and
myeloablative Bu/Cy regimen in 25 % (n 5 13) pts during second
Table 1. Survival Outcomes of Second Transplants: Patient Characteristics
Patient characteristics All patients (%) Auto/Auto Auto/Allo Allo/Allo
All patients 52 (100%) 12 (23%) 31 (60%) 9 (19%)
Matched Related Donors(MRD) 17 (33%) 0 (0%) 13 (25%) 4 (8%)
Unrelated Donors(URD) 21 (39%) 0 (0%) 18 (35%) 3 (6%)
Autologous Donors 12 (23%) 12 (23%) 0 (0%) 0 (0%)
Syngeneic Donors(Syn) 2 (4%) 0 (0%) 0 (0%) 2 (4%)
Overall survival (1yr) 47% (95% CI 40%-54%) 64% 37% 56%
Overall survival (5yrs) 32% (95% CI 25%-39%) 18% 32% 44%
Relapse at 1 yr 17 (33%) 4 (7%) 12 (23%) 1 (2%) Syn
Treatment related mortality (TRM) at 1 yr 8 (15%) 0 (0%) 5 (10%) 3 (6%)
Cause of death at 1 yr 4 (8%)%MOF;1(2%) GVHD 2 (4%) GVHD;1(2%) PTLD
Acute GVHD(III-IV) 2 (4%) 0 (0%) 1 (2%) 1 (2%)
Chronic GVHD( flare) 18 (35%) 0 (0%) 13 (25%) 5 (10%)
Chronic GVHD(De novo) 2 (4%) 0 (0%) 2 (4%) 0 (0%)
Auto indicates Autologous; Allo, allogeneic; GVHD, graft versus host disease.
Poster Session II S341transplant. Median survival of patients who survived beyond first 30
days after second transplant was 352 days (36-5777 days). The cu-
mulative incidence of grade III-IV acute GVHD was 10 % (n 5 2).
The cumulative incidences of relapse at 1 and 5 years were 33% and
43%respectively. Probabilities of overall survival at 1 and5 yearswere
47% (95% CI 40-54%) and 32% (95% CI 25%-39%), respectively.
Disease recurrence was most frequent primary cause of death in 33%
(n5 18) pts at 1year. TRM was 7% at 30 days; 11% at 100 days and
15% at one year. The causes of TRM at one year included GVHD: 6
% (n5 3), multi organ failure: 7% (n5 4), PTLD 2% (n5 1).
Conclusion: Patients undergoing second transplants can achieve
long term survival beyond 5 years. Relapse, GVHD or early TRM
are still causes of morbidity after second transplant.
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RADIATION EXPOSURE FROM DIAGNOSTIC PROCEDURES IN ALLOGE-
NEIC STEM CELL TRANSPLANTATION DOES NOT SIGNIFICANTLY IMPACT
OVERALL SURVIVAL OR NON-RELAPSE MORTALITY
Battiwalla, M., Fakhrejahani, F., Klotz, J., Pophali, P., Draper, D.,
Haggerty, J., McIver, Z., Chawla, K., Ito, S., Barrett, J. NHLBI,
NIH, Bethesda, MD
Introduction:Diagnostic radiology procedures in the context of al-
logeneic stem cell transplantation (ASCT) impose an unknown risk
of radiation exposure. We conducted a retrospective study on radia-
tion exposure in the peri-transplant period to define this risk.
Methods: 64 consecutive patients underwent sibling ASCT after
conditioning with TBI 1200 cGy or 400 cGy, fludarabine 125 mg/
m2 and cyclophosphamide 120 mg/kg utilizing CD34+ selected
PBSC and cyclosporine as GVHD prophylaxis. 24 patients received
5x10 e6 CD3+/kg donor lymphocytes selectively depleted of allor-
eactivity by ex vivo photodepletion.
Diagnostic procedures (X-rays, CT Scans, fluoroscopy, and nu-
clear medicine (NM)) were documented for each individual in three
periods (day-30 to 0, day +1-100 and day +101-200). Radiation expo-
sure was calculated using the ‘‘effective dose’’ (ED) in mSv by mea-
surement or from literature review. Overall survival (OS) and
nonrelapse mortality (NRM) were evaluated in 55 subjects who sur-
vived.200 days in univariate analysis andmultivariable Coxmodels.
The variables for the cumulative and the periodic ED were forced
into the models.
Results: Patients underwent a median of 11 X-rays, 10 CT-scans,
0 nuclear medicine studies, and 1 fluoroscopic procedure. The me-
dian cumulative radiation exposure from diagnostic radiology proce-
dures was 91.6 mSv (range 1.2-300.1), equivalent to \10% of
a standard 1200 TBI dose. 29% of the cumulative ED was delivered
fromday -30 to 0, 65% fromday +1-100 and only 6% fromday +101-
200. The relative contributions from CT scans, X-rays, fluoroscopy,
and NM were 88%, 6%, 5% and\1%, respectively.
In univariate analysis, the cumulative dose of incidental radiation
from day -30 to +200 (p\0.03) and from day -30 to +100 (p\0.05)
were significantly associated with OS. The cumulative dose of inci-
dental radiation from day-30 to +100was also significantly associated
with NRM (p\0.03).In multivariable analysis, cumulative doses of radiation lost statis-
tical significance and were displaced by serum creatinine and serum
albumin in the final models for OS and by albumin, acute GVHD
and photodepletion for NRM.
Conclusions: Total radiation exposure from diagnostic radiation
was only a small fraction of radiation utilized in conditioning. CT
scans provided 90% of the radiation exposure. While the cumula-
tive dose of incidental radiation exposure was associated with OS and
NRM in univariate analysis, it was not significant in multivariable
analysis.
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HIGH RESOLUTION 9/10 OR 10/10 HLA MATCHED UNRELATED DONOR
STEM CELLS CONTRIBUTE A BETTER OUTCOME OF TRANSPLANT IN SE-
VERE THALASSEMIA PATIENTS
Hongeng, S., Pakakasama, S., Anurathapan, U., Sirachainan, N.,
Songdej, D., Chuansumrit, A. Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
We reviewed transplant outcome in 34 consecutive children and
adolescents with severe thalassemia who underwent allogeneic stem
cell transplantation with unrelated donors between September
1992 and July 2011.Thefirst cohort 22 patients underwent transplant
from 4/6, 5/6 or 6/6 allele HLA matched unrelated donors and the
second cohort 12 patients underwent transplant from 9/10 or 10/10
HLA matched unrelated donors. The myeloablative conditioning
regimen (MC) consisted of cyclophosphamide, busulfan (BU), flu-
darabine (FLU) and antithymocyte globulin (ATG) and nonmyeloa-
blative (NC) consisted of BU, FLU and ATG. The GVHD
prophylaxis for MC consisted of tacrolimus and MTX and for NC
consisted of tacrolimus andMMF.The purpose of NCwas for toxic-
ity reducing in the patients older than 10 years of age. Of 34 patients,
29 received bone marrow, 4 received peripheral blood and 1 received
cord blood stem cells. The 2-year thalassemia-free survival rate for
the first 22 cohort patients was 71% and 93% for the second cohort
12 patients (p 5 0.045). We suggest that high resolution 9/10 or
10/10 matched unrelated donor stem cells may significantly improve
the thalassemia free survival among severe thalassemia patients
who underwent unrelated donor transplantation.
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CLINICAL OUTCOMES AND COSTS OF SECOND ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION
Khera, N.1, Storer, B.E.1, Chapko, M.K.2, Lee, S.J.1 1Fred Hutchinson
Cancer Research Center, Seattle, WA; 2VA Puget Sound, Seattle, WA
Background: In this era of growing health care costs, the decision to
proceed with a second allogeneic transplant has financial as well as
clinical implications.
Methods: We analyzed all medical costs for the transplant process
from the beginning of conditioning to 100 days after the transplant
for 55 patients who underwent second allogeneic transplants from
1/19/05 to 4/9/10 at the University of Washington/Seattle Cancer
